title: Tezacitabine enhances the DNA-directed effects of fluoropyrimidines in human colon cancer cells and tumor xenografts.
abstract: Tezacitabine is a nucleoside analogue characterized by a dual mechanism of action. Following intracellular phosphorylation, the tezacitabine diphosphate irreversibly inhibits ribonucleotide reductase, while the tezacitabine triphosphate can be incorporated into DNA during replication or repair, resulting in DNA chain termination. In the present study we have investigated the effect of the combination of tezacitabine and 5-fluorouracil (5-FU) or 5-fluoro-2'-deoxyuridine (FUdR) on HCT 116 human colon carcinoma cells and xenografts. We used response surface analysis (RSA) and clonogenic assay to evaluate combination effects of tezacitabine and 5-FU. Tezacitabine is antagonistic when combined with 5-FU in the RSA assay and does not effect the clonogenicity of HCT 116 cells when compared with cells treated with 5-FU alone. However, when combined sequentially with FUdR, tezacitabine leads to potentiation of cell killing in the clonogenic assay, additivity in the RSA assay, and increased apoptosis when compared to FUdR alone, suggesting that cytotoxicity of fluoropyrimidines such as FUdR that have more DNA-directed effects can be potentiated by tezacitabine. We also report that oral administration of the fluoropyrimidine capecitabine, an oral prodrug of 5-FU, in combination with tezacitabine shows statistically significant additivity in the HCT 116 xenograft model. This interaction may be explained by the finding that tezacitabine elevates activity of thymidine phosphorylase (TP), the enzyme required for activation of the capecitabine prodrug in tumors. Our results provide evidence that tezacitabine enhances the DNA-directed effects of fluoropyrimidines in human colon cancer cells and may modulate the antitumor activity of fluoropyrimidines.
authors.affiliation: Department of Pharmacology, Chiron Corporation, Emeryville, CA 94608, United States. pietrotaverna@hotmail.com
authors.forename: Pietro
authors.initials: P
authors.lastname: Taverna
authors.forename: Katherine
authors.initials: K
authors.lastname: Rendahl
authors.forename: Dragana
authors.initials: D
authors.lastname: Jekic-McMullen
authors.forename: Yi
authors.initials: Y
authors.lastname: Shao
authors.forename: Kim
authors.initials: K
authors.lastname: Aardalen
authors.forename: Fernando
authors.initials: F
authors.lastname: Salangsang
authors.forename: Laura
authors.initials: L
authors.lastname: Doyle
authors.forename: Eddie
authors.initials: E
authors.lastname: Moler
authors.forename: Barbara
authors.initials: B
authors.lastname: Hibner
mesh_terms: D017209:Apoptosis / Q000187:drug effects; D045744:Cell Line, Tumor; D003110:Colonic Neoplasms / Q000201:enzymology / Q000473:pathology*; D004247:DNA / Q000187:drug effects*; D004249:DNA Damage; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000494:pharmacology; D005467:Floxuridine / Q000494:pharmacology*; D005472:Fluorouracil / Q000494:pharmacology*; D006801:Humans; D013939:Thymidine Phosphorylase / Q000378:metabolism; D013940:Thymidylate Synthase / Q000378:metabolism; D014183:Transplantation, Heterologous
chemical_list: D005467:Floxuridine; D003841:Deoxycytidine; D004247:DNA; D013940:Thymidylate Synthase; D013939:Thymidine Phosphorylase; D005472:Fluorouracil; C086432:tezacitabine